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Clostridium difﬁcile is a leading cause of infectious diarrhea in hematopoietic stem cell transplant (HSCT)
recipients. Asymptomatic colonization of the gastrointestinal tract occurs before development of C. difﬁcile
infection (CDI). This prospective study examines the rates, risk factors, and outcomes of colonization with
toxigenic and nontoxigenic strains of C. difﬁcile in HSCT patients. This 18-month study was conducted in
the HSCT unit at the Karmanos Cancer Center and Wayne State University in Detroit. Stool samples from the
patients who consented for the study were taken at admission and weekly until discharge. Anaerobic culture
for C. difﬁcile and identiﬁcation of toxigenic strains by PCR were performed on the stool samples.
Demographic information and clinical and laboratory data were collected. Of the 150 patients included in the
study, 29% were colonized with C. difﬁcile at admission; 12% with a toxigenic strain and 17% with a non-
toxigenic strain. Over a 90-day follow-up, 12 of 44 (26%) patients colonized with any C. difﬁcile strain at
admission developed CDI compared with 13 of 106 (12%) of patients not colonized (odds ratio [OR], 2.70; 95%
conﬁdence interval [95% CI], 1.11 to 6.48; P ¼ .025). Eleven of 18 (61%) patients colonized with the toxigenic
strain and 1 of 26 (4%) of those colonized with nontoxigenic strain developed CDI (OR, 39.30; 95% CI, 4.30 to
359.0; P < .001) at a median of 12 days. On univariate and multivariate analyses, none of the traditional
factors associated with high risk for C. difﬁcile colonization or CDI were found to be signiﬁcant. Recurrent CDI
occurred in 28% of cases. Asymptomatic colonization with C. difﬁcile at admission was high in our HSCT
population. Colonization with toxigenic C. difﬁcile was predictive of CDI, whereas colonization with a non-
toxigenic C. difﬁcile appeared protective. These ﬁndings may have implications for infection control strategies
and for novel approaches for the prevention and preemptive treatment of CDI in the HSCT patient population.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION
Diarrhea is a major cause of morbidity in hematopoietic
stem cell transplant (HSCT) recipients [1]. The etiology ofdgments on page 163.
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ty for Blood and Marrow Transplantation.diarrhea in this population is often multifactorial, including
gastrointestinal graft-versus-host disease (GVHD), adverse
effects of chemotherapy, and infections. Recent single-center
retrospective studies suggest Clostridium difﬁcile infection
(CDI) is an important cause of infectious diarrhea in HSCT
patients, with rates of 10% to 24% [1-4] and a 1-year incidence
of 9.2% [5]. Furthermore, about 20% of the general
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recurrence of CDI despite therapy. However, the epidemi-
ology of CDI has been evolving, with a signiﬁcant increase in
the incidence and severity of CDI in the last decade, in part
due to the emergence of an easily transmissible and virulent
North American pulsed-ﬁeld gel electrophoresis type 1
(NAP1) strain of C. difﬁcile [7,8]. The impact of the NAP-1
strains on the rates of CDI in the HSCT population is unknown.
Asymptomatic colonization with toxigenic C. difﬁcile
precedes symptomatic CDI. Colonization is common among
hospitalized patients, with progression to CDI upon disrup-
tion of the enteric microbiome after antibiotic therapy [9].
Asymptomatic carriage of C. difﬁcile may also contribute to
nosocomial transmission [10-13]. A recent multicenter pro-
spective study of general hospitalized patient population
reported a C. difﬁcile colonization rate of 4.4% at admission
and 3% after hospitalization [14]. Colonizationwas associated
with recent hospitalization, prolonged length of hospital
stay, and exposure to chemotherapy and proton pump in-
hibitors (PPI) and H2 blockersdfactors prevalent in the HSCT
population [14]. Two recent studies in HSCT recipients using
enzyme immunoassay and PCR assays have reported rates of
colonization with toxigenic C. difﬁcile of 10.7% and 39% [3,4].
Early studies suggest colonization with nontoxigenic strains
of C. difﬁcile might protect against colonization with toxi-
genic strains of C. difﬁcile and subsequent CDI [15]. However,
rates of colonization with nontoxigenic C. difﬁcile and
comparative outcomes associated with colonization with
toxigenic and nontoxigenic strains have not been reported in
the HSCT population.
A prior study done at our institution reported a 9-fold
higher rate of CDI in hospitalized HSCT patients compared
with the general patient population (24 of 10,000 patient
days versus 2.6 of 10,000 patient days) [16]. Given the high
rates of CDI and limited data on the epidemiology of
C. difﬁcile colonization and infection in HSCT patients, this
prospective study aims to do the following: (1) report rates of
colonization and infection with toxigenic and nontoxigenic
C. difﬁcile in hospitalized HSCT patients using culture and
PCR testing, (2) evaluate relevant risk factors associated with
colonization and infection, and (3) examine outcomes asso-
ciated with colonization and infection.
PATIENTS AND METHODS
Study Population
The study was conducted at the Bone Marrow Transplant (BMT) inpa-
tient unit at the Karmanos Cancer Institute and Wayne State University in
Detroit, Michigan. All HSCT patients admitted to the BMT unit between
December 1, 2010 and June 31, 2012 were invited to participate in the study.
We included all HSCT recipients admitted during the study period regardless
of the time from HSCT. Patients who signed informed consent for the study
were requested to provide a stool sample within 72 hours of admission and
weekly thereafter until discharge from the hospital. Patients were excluded
if they were diagnosed with CDI within 72 hours of hospital admission or if
they were unable to provide a stool sample within 72 hours of admission.
The study was approved by the institutional review board at Wayne State
University, Detroit, Michigan.
Study methodology
In order to detect colonization with C. difﬁcile the study was designed to
collect a stool specimen at admission and then weekly thereafter as long as
the patient remained in hospital. No samples were collected for the study
after hospital discharge. The research assistant obtained weekly stool
samples for the study as per study schedule. The study stool samples were
tested in the research laboratory using stool cultures followed by C. difﬁcile
toxin PCR. This was done in order to detect colonization with toxigenic and
non-toxigenic strains of C. difﬁcile. The results were not provided to the
clinicians.The treating physician and other providers ordered stool testing as clini-
cally indicated if C. difﬁcile infectionwas suspected. These sampleswere tested
in the hospital clinical microbiology laboratory using C. difﬁcile toxin PCR.
Microbiology Methodology
The stool samples were stored at 70C and batched for testing. The
testing of study samples was performed in the research laboratory. Stool
samples were inoculated on cycloserine cefoxitin fructose agar enriched
with horse blood and incubated at 35C under anaerobic conditions. The
presumptive identiﬁcation of C. difﬁcile was made after colonies with the
characteristic yellow/off-white, ground-glass morphology grown of cyclo-
serine cefoxitin fructose agar enriched with horse blood showed gram
positive/gram variable bacilli in Gram stain.
The samples that were culture positive for C. difﬁcilewere further tested
by PCR to identify toxigenic strains. EasyMag instrument (BioMerieux,
Durham, NC, USA) was used for DNA extraction from stool samples before
PCR. Brieﬂy, 500-mL lysis buffer was added to 500 mL of liquid stool sample
and then allowed to sit for 10 minutes. The sample was centrifuged at
16,000 rpm for 1 minute. Then, 200 mL of cleared lysate supernatant was
extracted and the DNA was eluted into 50 mL of elution buffer. Detection of
toxigenic strains of C. difﬁcile was performed by using the LightMix Kit
Clostridium difﬁcile (TIB Mol Biol, Adelphia, NJ, USA) and LightCycler Fast-
Start DNA Master HybProbe (Roche Diagnostics, Indianapolis, IN, USA) on
the LightCycler 1.2 instrument as recommended by themanufacturer. A 176-
bp fragment of the C. difﬁcile tcdC gene and a 158-bp fragment of the 18bp
deletion found in mutant C. difﬁcile del. strains BI/NAP1/027 (ribotype 027)
were ampliﬁed. The resulting PCR fragments were analyzed with
hybridization probes labeled with Roche LightCycler Red 640 (channel 640).
The distinction between C. difﬁcile del and wild-type C. difﬁcilewas made by
melting temperature analysis of the PCR products. The C. difﬁcile del DNA
exhibits a melting temperature of 65C in channel 640. C. difﬁcile shows a
broader melting proﬁle, between 55C and 65C. The PCR reaction is
monitored by an additional PCR product of 349bp formed from the internal
control. The supplied vials of C. difﬁcile DNA with known concentrations
permitted estimation of the quantity of the C. difﬁcile DNA in the samples
(linear measuring range of the assay is 100 to 1,000,000 copies C. difﬁcile
DNA). The study results were not utilized for patient care.
Study Design
A prospective cohort study was performed. All HSCT patients colonized
with C. difﬁcile at admission were considered cases and patients not colo-
nized with C. difﬁcile were the controls. Demographic, clinical, and labora-
tory data and outcomes were collected from review of the electronic
medical records. Patient data were reviewed for the 30 days preceding
admission to the BMT unit to identify potential risk factors for C. difﬁcile
colonization and infection. Similarly, patient data were reviewed for 90 days
after study enrollment to evaluate outcomes. The risk factors evaluated
included prior CDI, recent hospitalization or clinic visit, and use of antibi-
otics and PPI. We also reviewed variables related to the HSCT, including
indication, type of transplantation, and presence of GVHD. The Charlson
comorbidity index was used to grade the severity of comorbid illnesses and
the Karnofsky score was used to assess performance status. In patients who
developed CDI, the severity of CDI, treatment used for CDI, relapse and
recurrence rates, number of recurrences, and time to recurrence were
evaluated. The outcomes evaluated included occurrence of CDI in patients
colonized with C. difﬁcile; in those with CDI, outcomes examined included
intensive care unit admission, need for colectomy, or death related to CDI.
Deﬁnitions
C. difﬁcile colonization was deﬁned as isolation of C. difﬁcile from stool
specimen on culture in a patient without diarrhea. CDI was deﬁned as
presence of diarrhea conﬁrmed with positive stool PCR for C. difﬁcile done in
the clinical laboratory. Testing for C. difﬁcilewas performed at the discretion
of the treating physician. Per laboratory protocol, only diarrheal stools were
accepted for C. difﬁcile testing. Recurrent CDI was deﬁned as a new onset of
diarrhea and a C. difﬁcileepositive stool PCR assaywithin 90 days of previous
CDI. There is no standardized deﬁnition of severe CDI; however, several
parameters associated with severe disease are white count > 15,000 cells/
mm3, elevation of serum creatinine >1.5 times the baseline, abdominal
distension, and low albumin [17,18]. Because several of these parameters
may be abnormal in patients with HSCT, for the purposes of this study, severe
CDI was deﬁned as the presence of the following: CDI necessitating
admission to an intensive care unit or resulting in colectomy or death within
30 days after disease onset [19]. Neutropenia was deﬁned as absolute
neutrophil count less than 500 cells/mm3. Lymphopenia was deﬁned as
absolute lymphocyte count less than 300 cells/mm3. Only biopsy-proven
cases of GVHD of the gastrointestinal tract were included.
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Data analyses were performed using SPSS version 21 (IBM, Armonk,
NY). Chi-squared and Fisher exact tests were used to compare categor-
ical variables among patients colonized with C. difﬁcile versus patients
not colonized with C. difﬁcile and among patients colonized with toxi-
genic C. difﬁcile strains versus patients colonized with nontoxigenic
strains. T-test and Wilcoxon rank-sum test were used to analyze
continuous variables among the different groups. Variables with a P
value of less than .10 in bivariate analyses were included as candidates
for multivariate analyses. Logistic regression with backwards selection
was performed to select for variables in the ﬁnal model. Variables
excluded in the backwards selection model that changed the b-co-
efﬁcients of selected variables by >10% were considered confounders
and were added back to the model. All P values were 2 sided and used a
5% level of signiﬁcance.RESULTS
Study Patients
During the 18-month study period, a total of 533 HSCT
patients were admitted to the BMT unit. Of these, 21 patients
were not eligible as they had diarrhea, were diagnosed with
community-onset CDI, or had CDI diagnosed within 72 hoursNo. of patients adm
BMT unit during stu
N = 533
No. of patients
consented to par
N = 157
No. of patients inclu
N = 15
No. of patients colonized with 
C. difficile at admission
N = 44 (29%)
No. of patients colonized with 
toxigenic C. difficile
N = 18 (12%)
No. of patients colonized with 
non-toxigenic C. difficile
N = 26 (17%)
Figure 1. Study enrollment and coloof admission to the unit. Of the remaining eligible 512 pa-
tients, 157 agreed to participate in the study. Seven patients
were excluded, as they could not provide a stool sample for
testing within 72 hours of admission. The 150 evaluable
patients provided a total of 430 stool samples for testing. The
percentage of patients who provided sequential weekly stool
samples for testing were as follows: at admission, 100%;
week þ1, 67%; week þ2, 48%; week þ3, 32%; week þ4, 16%;
week þ5, 13%; and week þ6, 7%. No samples were collected
for the study after hospital discharge. Hence the drop off rate
reﬂects patients being discharged from the hospital. 100% of
enrolled patients provided a sample at admission and all
enrolled patients provided weekly stool samples as long as
they remained in hospital.Rates and Outcomes
Rates and potential risk factors
Of the 150 patients included in the study, 44 (29%) were
found to be C. difﬁcile culture positive at the time ofitted to 
dy period 
No. of patients not eligible
N = 21
No. of patients who 
declined 
N = 355 who 
ticipate
 
No. of patients who could 
not provide stool sample 
within 72 hours of 
admission
N = 7 
ded in analysis 
0
No. of patients not colonized with 
C. difficile at admission 
N = 106 (71%)
nization status at admission.
Table 1
Characteristics of HSCT Patients with and without C. difﬁcile Colonization at Admission
Variable Colonized Patients
n ¼ 44
Noncolonized Patients
n ¼ 106
OR 95% CI P Value
Age, mean (SD), yr 50.95 (12) 51.07 (13) .96
Female gender 26 (59) 35 (33) 2.93 1.42-6.05 .003
Ethnicity
White race 29 (66) 73 (69)
Black race 4 (9) 11 (10) .92 .27-3.11 .89
Other 11 (25) 22 (21) 1.26 .54-2.92 .59
Charlson score  3 17 (39) 53 (50) .63 .31-1.29 .20
Karnofsky score  70 39 (88.6) 94 (88.7) .99 .33-3.02 .99
Prior hospitalization* 15 (34) 28 (26) 1.44 .68-3.08 .34
Prior clinic visit* 42 (95.5) 98 (92.5) 1.71 .35-8.42 .50
Prior CDI* 3 (7) 15 (14) .44 .12-1.62 .21
Antibiotic use* 33 (75) 76 (72) 1.18 .53-2.64 .68
PPI use* 19 (43) 59 (56) .61 .30-1.23 .16
Steroid use* 18 (41) 43 (41) .99 .49-2.04 .99
Immunosuppressant use* 31 (70.5) 80 (76) .75 .34-1.64 .46
Indication for HSCT
Leukemia 31 (70.5) 76 (72) .94 .43-2.04 .88
Lymphoma 10 (22.7) 24 (22.6) 1.01 .43-2.33 .99
Solid tumor 6 (13.6) 14 (14) .96 .35-2.65 .93
Allogeneic transplantation 43 (98) 100 (94) 2.58 .30-22.10 .37
Unrelated donor source 34 (79) 61 (62) 2.35 1.02-5.45 .042
GVHD* 10 (23) 24 (23) 1.01 .43-2.33 .99
Gastrointestinal GVHD* 8 (18) 22 (21) 1.46 .56-3.77 .43
Neutropenia* 10 (23) 24 (23) 1.01 .43-2.33 .99
Lymphopenia* 29 (66) 62 (58.5) 1.37 .66-2.86 .40
Low albumin (<2.5 g/dL)* 6 (14) 12 (11) 1.24 .43-3.53 .69
Data presented are n (%), unless otherwise indicated.
* Assessed within 30 days before hospital admission.
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Of the 44 colonized patients, 18 (41%) were colonized with
toxigenic strain of C. difﬁcile and 26 (59%) were colonized
with nontoxigenic strain. Figure 1 summarizes the enroll-
ment and colonization status.
Table 1 shows the baseline characteristics of the study
population. Compared with the noncolonized patients,
colonized patients were more commonly women (odds
ratio [OR], 2.92; 95% conﬁdence interval [CI], 1.42 to 6.05;
P ¼ .003). Unrelated donor status was the only other
variable associated with C. difﬁcile colonization (OR, 2.35;
95% CI, 1.02 to 5.45; P ¼ .042). The other characteristics
related to demographics, potential risk factors for C. difﬁcile
acquisition, and transplantation-related variables were
comparable in the 2 groups. In a regression model adjusted
for confounding effects of relation to donor, the only inde-
pendent predictor of colonization with C. difﬁcile was fe-
male gender (P ¼ .007). Likewise, as summarized in Table 2,
the demographics and other characteristics were similar in
study patients colonized with toxigenic and nontoxigenic
strains of C. difﬁcile.
Outcomes
In the follow up-period of 90 days from study enroll-
ment, 12 of 44 (26%) patients colonized with any C. difﬁcile
strain developed CDI compared with 13 of 106 (12%) of
patients not colonized with C. difﬁcile (OR, 2.70; 95% CI, 1.11
to 6.48; P ¼ .025). Of the colonized patients, 11 of 18 (61%)
colonized with a toxigenic strain of C. difﬁcile and 1 of 26
patients (4%) colonized with a nontoxigenic strain of
C. difﬁcile developed CDI (OR, 39.30; 95% CI, 4.30 to 359.0;
P < .001) (Table 3). In the HSCT patients colonized with
toxigenic C. difﬁcile, the presence of potential risk factors for
CDI, including exposure to antibiotics, PPIs, and chemo-
therapy, were similar in those who developed CDI and those
who did not.CDI was primarily characterized by diarrhea (100%),
fever (56%), and abdominal pain (32%). Leukocytosis
of 15,000/mm3 was present in 16% patients at time of CDI
(Table 4). Most patients (76%) with CDI were treated with
oral vancomycin. Recurrent CDI occurred in 28% of patients
within the 90-day follow-up. No cases of severe CDI
occurred as deﬁned by the study criteria, and no patients
died as a result of CDI.
Of the 150 patients in the study cohort, 127 patients were
enrolled in the study within 100 days of HSCT. The rate of
gastrointestinal GVHDwithin 100 days of the transplantation
in these patients was 40% (10 of 25) in those who developed
CDI compared with 36% (36 of 102) in patients who did not
develop CDI.
DISCUSSION
This prospective study shows that colonization with
toxigenic and nontoxigenic C. difﬁcile is common and present
in about one quarter of our HSCT patients at the time of
hospitalization. The study also demonstrates that the
majority of patients colonized with toxigenic C. difﬁcile
will develop symptomatic CDI within 2 weeks of hospital
admission. In contrast, colonization with nontoxigenic
C. difﬁcile may be protective against CDI.
In our HSCT population, the overall rates of colonization
with C. difﬁcile at hospital admission was high at 29.3%, of
which 17%were due to a nontoxigenic strain and 12% due to a
toxigenic strain of C. difﬁcile. Rates of asymptomatic carriage
of toxigenic C. difﬁcile in recent studies has ranged from 0.6%
in the geriatric population [20] to up to 15% in a general
patient population [14,21]. Our rate of asymptomatic carriage
of toxigenic C. difﬁcile of 12% is comparable to rates recently
reported from other HSCT centers. Alasmari et al. reported
an overall C. difﬁcile colonization rate of 21%, with 6% due to
nontoxigenic and 15% due to toxigenic strains in HSCT pa-
tients at hospitalization [22]. Using a 2-tier assay of glutamate
Table 2
Characteristics of HSCT Patients Colonized with Toxigenic and Nontoxigenic C. difﬁcile
Variable Colonized with Toxigenic C.difﬁcile
n ¼ 18
Colonized with Nontoxigenic C. difﬁcile
n ¼ 26
OR 95% CI P Value
Age, mean (SD), yr 51 (13) 50.77 (12) .91
Female gender 8 (44) 10 (56) .78 .23-2.65 .69
Ethnicity
White race 13 (72) 16 (62) Reference
Black race 0 4 (15) .99
Other 5 (28) 6 (23) 1.03 .25-4.14 .97
Charlson score  3 7 (39) 10 (38.5) 1.02 .30-3.50 .97
Karnofsky score  70 17 (94) 22 (85) 3.10 .32-30.25 .63
Prior hospitalization* 3 (17) 12 (46) .23 .05-1.01 .057
Prior clinic visit* 17 (94) 25 (96) .68 .04-11.63 1.00
Prior CDI* 2 (11) 1 (4) 3.13 .26-37.36 .56
Antibiotic use* 15 (83) 18 (69) 2.22 .50-10.00 .48
PPI use* 6 (33) 3 (50) .50 .14-1.74 .27
Steroid use* 7 (39) 11 (42) .87 .25-2.96 .82
Immunosuppressant use* 11 (61) 20 (77) .47 .13-1.76 .26
Indication for HSCT
Leukemia 12 (67) 19 (73) .74 .20-2.73 .65
Lymphoma 4 (22) 6 (23) .95 .23-4.01 1.00
Solid tumor 2 (11) 4 (15) .69 .11-4.22 1.00
Allogeneic HSCT 18 (100) 25 (96) .96 .89-1.04 1.00
Unrelated donor source 14 (78) 20 (80) .88 .20-3.85 1.00
GVHD* 2 (11) 8 (31) .28 .05-1.52 .16
Gastrointestinal GVHD* 2 (11) 6 (23) .16 .02-1.43 .12
Neutropenia 2 (11) 8 (31) .28 .05-1.52 .16
Lymphopenia 10 (56) 19 (73) .46 .13-1.64 .23
Low albumin 3 (17) 3 (11.5) 1.53 .27-8.63 .67
Data presented are n (%), unless otherwise indicated.
* Assessed within 30 days before hospital admission.
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minhent et al. found that 10.7% of patients undergoing HSCT
were colonized with toxigenic C. difﬁcile at admission [3].
Kinnebrew et al., using a PCR assay, noted rates of colonization
with toxigenic C. difﬁcile of 39% during the pretransplantation
conditioning and up to day 35 after HSCT, with most cases
detected in the pretransplantation period [4]. As expected,
rates of detection are higher at HSCT centers utilizing the
more sensitive PCR assays. The sensitive PCR assays do not
distinguish between colonization and CDI and may poten-
tially overestimate cases of CDI in the HSCT population, in
whom diarrhea is a common symptom. The high rates of
colonizationwith C. difﬁcile in the HSCT population, compared
with the general population, may reﬂect the acquisition
through frequent exposures to the health care environment,
antibiotics, antacids, and chemotherapy. Furthermore, the
underlying immune dysfunction in HSCT patients may
contribute to the persistent carriage of C. difﬁcile.
Studies since the 1980s have reported a signiﬁcant asso-
ciation between colonization with C. difﬁcile and older age,
recent hospitalization, exposure to antibiotics, PPI, H2
blockers, chemotherapy, corticosteroids, and chronic dialysis
[10,14,19,21,23,24]. None of these factorswere independently
associated with C. difﬁcile colonization in our HSCT patients.Table 3
Odds Ratios of Occurrence of C. Difﬁcile Infection Based on Colonization Status at T
Colonized
with C. difﬁcile
n ¼ 44
Not Colonized
with C. difﬁcile
n ¼ 106
OR (95% CI)
Occurrence of CDI, n (%) 12 (27%) 13 (12%) 2.70 (1.11-6.48)
Time from admission to CDI,
median [IQR], d
12 [7-25.25] 12 [7.5-19.5]
IQR indicates interquartile ratio.A similar lack of association with the traditional risk factors
and colonization with C. difﬁcile in HSCT recipients has been
reported [22]. Furthermore, in the HSCT population, use of
chemotherapy before conditioning, intensity of condition
regimen, and total body irradiation have been associated
with increased risk of CDI [4,5,25]. Studies have also reported
GVHD as a risk for the development of CDI in HSCT recipients
[5,25]. None of these factors were associated with coloniza-
tion or infection with C. difﬁcile in our study. It is likely that
these potential risk factors, such as exposure to the health
care environment, antibiotics, PPI, and chemotherapy, were
so prevalent in our HSCT population they could not serve as
independent predictors for C. difﬁcile colonization or infec-
tion. This observation suggests that, in the HSCT population,
screening based solely on clinical and epidemiological fac-
tors will not be useful in guiding targeted surveillance for
C. difﬁcile. In our study, women were more commonly colo-
nized at admission. Higher rates of colonization and CDI have
been noted in women, although postulated explanations
include greater contact with children, more clinic visits, and
more exposure to antibiotics; however, the exact reasons
remain unclear [7].
Notably, over a 90-day follow-up period, 27% of asymp-
tomatic patients colonized with C. difﬁcile developed CDIime of Hospital Admission
P Value Colonized
with Toxigenic
C. difﬁcile
n ¼ 18
Colonized with
Nontoxigenic
C. difﬁcile
n ¼ 26
OR (95% CI) P Value
.025 11 (61%) 1 (4%) 39.30 (4.30-359.0) <.001
.89 11 [7-23] 26 [26-26] .50
Table 4
Characteristics and Outcomes of Patients with C. difﬁcile Infection (n ¼ 25)
Characteristic(s) Value
Clinical features
Diarrhea 25 (100)
Fever 14 (56)
Abdominal pain 8 (32)
Treatment
Metronidazole 4 (16)
Vancomycin 19 (76)
Both 2 (8)
Recurrent CDI 7 (28)
<30 Days 4 (57% of recurrence)
30-90 Days 3 (43% of recurrence)
Complications of CDI
CDI-related colectomy 0 (0)
ICU admission for CDI 0 (0)
30-Day mortality 0 (0)
ICU indicates intensive care unit.
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colonized with toxigenic C. difﬁcile at admission developed
CDI (OR, 39.30; 95% CI, 4.30 to 359.0; P< .001), at a median of
12 days. Although an early study reported asymptomatic
carriage of C. difﬁcile was associated with a low risk (1%) of
CDI [26], more recent studies in the general population have
reported rates of CDI ranging from 14% to 51% over 5 to
18 months of follow-up in patients colonized with toxigenic
C. difﬁcile [23,27-29]. The high OR signifying increased risk of
CDI in our patients colonized with toxigenic C. difﬁcile is
comparable to ORs of 68.5% [3] and 17.6% [4] reported in the
2 recent studies. The high rate of CDI in HSCT patients
colonized with toxigenic C. difﬁcile might reﬂect the under-
lying immunocompromised state of these patients, as well as
exposure to several other risk factors, such as antibiotics,
PPIs, and chemotherapy. The attenuated immune response
and prevalence of hypogammaglobulinemia in HSCT patients
may contribute to development of CDI. Higher concentra-
tions of IgA and IgM were reported in asymptomatic carriers
of C. difﬁcile compared with patients with symptomatic CDI
[30]. Furthermore patients who developed higher levels of
IgG to C. difﬁcile toxin A after colonization with C. difﬁcile
were more likely to remain asymptomatic carriers rather
than develop CDI [27,31,32]. A phase 2 trial examining the
clinical effectiveness of a human monoclonal antibody to
C. difﬁcile toxin A and B, to prevent recurrent CDI, has just
been completed [33].
Strikingly, only 1 (4%) patient colonized with non-
toxigenic strain developed CDI days during the 90-day
follow-up period, compared with 61% patients colonized
with toxigenic C. difﬁcile. A similar observationwas noted in a
recent study by Hung et al. with rates of CDI over an 18-
month follow-up of 14%, 0%, and .9% in general patients
colonized with toxigenic C. difﬁcile, nontoxigenic C. difﬁcile,
and no colonization, respectively [29]. The mechanism of the
protective effect is unknown, but a plausible explanation is
that nontoxigenic C. difﬁcile competes with toxigenic strains
and inhibits their colonization. This has important clinical
implications, as colonization with nontoxigenic C. difﬁcile
may be protective towards development of CDI in HSCT
population. This protective effect has been described in
hamster models [34,35]. In healthy adult human subjects,
Villano et al. reported good tolerance to non-toxigenic
C. difﬁcile VP20621/NTCD-M3 spores in a recent phase 1
study [15]. A follow-up phase 2 randomized controlled study
reported that oral administration of spores of NTCD-M3
strain of non-toxigenic C. difﬁcile, successfully colonized thegastrointestinal tract of patients treated for CDI and signiﬁ-
cantly reduced CDI recurrence [36].
Clinical CDI features in HSCT population were similar to
generally reported symptoms of diarrhea, fever, and
abdominal pain. Severe CDI and mortality rates of up to 9%
have been reported in general population from community-
acquired CDI [37,38], with higher death rates in the older
population. However, severe CDI, as deﬁned by McDonald
et al. [39] was not found in any patient in our study. This is
similar to previously reported low occurrence of severe CDI
in the HSCT population, both allogeneic and autologous
[1,4,40]. In our study population, 22 out of the 25 CDI pa-
tients were treated with vancomycin or both vancomycin
and metronidazole as ﬁrst-line therapy for the ﬁrst episode
of CDI. It is unclear if the use of vancomycin as initial therapy
might have resulted in a more benign course of disease.
Recurrence within 90 days was noted in 6 of 25 (24%)
patients in our study. Of these, 4 (16%) recurred within
30 days of ﬁrst episode and 2 (8%) had symptoms after
30 days. The recurrence rate of CDI varies from about 8% to
22% in studies of CDI in HSCT patients [1,3,5] and is compa-
rable to rate of 25% reported in the general population [6].
The high rates of recurrence in our study may also be due to
the longer follow-up period of 90 days rather than the usual
4 to 8 weeks of follow-up used in other studies. Newer
agents, such as ﬁdaxomicin, that are associated with fewer
recurrences of CDI [6] may be preferred in the HSCT
population.
Retrospective studies have reported increased risk of the
development of GVHD and gastrointestinal GVHD in patients
with CDI [2,5,41]. In our study, the rates of development of
GVHD within 100 days of HSCT were comparable in patients
with CDI and those without. However, our study had too few
patients to draw any ﬁrm conclusions. Two recent prospec-
tive studies reported no association with GVHD in patients
with CDI [3,4]. Given the limited data, it is yet unclear if any
association exists between GVHD and C. difﬁcile colonization
and infection.
Our study has several limitations. The study was con-
ducted at a single center and, hence, the ﬁndings might not
be applicable to other transplantation centers. The 157 pa-
tients who consented to participate in the study comprised
about 30% of the 533 eligible patients admitted to the unit
during the study period. Hence, the ﬁnding might not be
representative of all of our HSCT patients. The culture used
for the detection of C. difﬁcile in our study is not as sensitive
as PCR and may not have identiﬁed all patients who were
colonized with toxigenic C. difﬁcile [42]. However, we used
cultures as we wished to identify and assess the outcomes
associated with colonization with both toxigenic and non-
toxigenic C. difﬁcile. Since strain typing was not performed it
was not possible to conﬁrm if the colonizing toxigenic strain
was the same strain that caused CDI.
C. difﬁcile colonization at admission is common in our
HSCT population. Colonization with toxigenic strains of
C. difﬁcile seems predictive of subsequent CDI. Notably,
colonization with nontoxigenic strains appears to be pro-
tective against CDI in HSCT patients. Severe disease CDI is
uncommon in this population and no associationwith GVHD
was evident. Larger multicenter studies are necessary to
conﬁrm these ﬁndings. High rates of asymptomatic coloni-
zation at admission, with potential for unidentiﬁed nosoco-
mial transmission, have implications for infection control.
Novel strategies for prevention of CDI such as the “pre-
emptive” therapy of patients colonized with toxigenic
T. Jain et al. / Biol Blood Marrow Transplant 22 (2016) 157e163 163C. difﬁcile, use of monoclonal antibodies to C. difﬁcile toxin A
and B, or the therapeutic use of nontoxigenic strains of
C. difﬁcile need to be explored in this population.
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